Florida based P&C insurance company trading at a 30% discount to book value of $13
Heritage Holdings (HRTG) is selling off on the Hurricane Irma headlines. The shares are now trading at $9, a 30% discount to book value of $13. The market has dumped the entire group, including peers: HC
Amazon (AMZN) is the master of everything. They own the retail space, are a dominant force in data storage, have hits in hardware and are quietly a logistics master. But the real prize -- and its not AWS -- it is Prime. Thats what could make Whole Foods interesting -- effectively turning it into
Loxo Oncology, Inc. (NASDAQ:LOXO) has shown excellent results from its drug candidate Larotrectinib, and now is an excellent entry point ahead of new data. The company will update on December 4-5, 2017, on previously impressive top-line data from the pediatric trial (SCOUT). Previous data on this was presented at the American Society of Clinical Oncology (ASCO) meeting in June.
Tesla saw a worker injury rate that is 31% higher than the industry average at its only electric-car manufacturing plant in 2015, and the rate only slightly dipped last year, a new study finds.
Also, more serious injuries, those that resulted in days off work, restricted duty or a transfer, was almost double the industry average in 2015, according to the report from a non-profit called Worksafe....More>>>
This article is reprinted by permission from NextAvenue.org.
After attending so manyfuneralsthat rarely reflected the vibrant lives of friends and familythey were meant to honor, a group of fed-up older people in Rotorua, New Zealand created what they call a Coffin Club.
In a short documentary video(with a whimsical musical number) from Loading Docs, members of the Kiwi Coffin Club....More>>>
The U.S. Securities and Exchange Commission (SEC) has taken down a cryptocurrency scam offering. According to the SEC website, the commission has obtained an emergency asset freeze to halt a fast-moving initial coin offering (ICO) fraud. While this is not technically a bitcoin fraud, the reality is that it shows 1) how willing the public is to chase gains and 2) how willing potentially scammers....More>>>
Loxo Oncology, Inc. (NASDAQ:LOXO) has shown excellent results from its drug candidate Larotrectinib, and now is an excellent entry point ahead of new data. The company will update on December 4-5, 2017, on previously impressive top-line data from the pediatric trial (SCOUT). Previous data on thi
Description of the opportunity and investment thesis
CRHM represents a compelling risk/reward opportunity in the form of a rapidly growing leader in anesthesiology services for GIs in the US and Canada. We believe the company is undervalued on an absolute and relative basis, currently